Company Description
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains.
The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | James F. Oliviero III, C.F.A. |
Contact Details
Address: 95 Sawyer Road, Suite 110 Waltham, Massachusetts 02453 United States | |
| Phone | 781-652-4500 |
| Website | checkpointtx.com |
Stock Details
| Ticker Symbol | CKPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651407 |
| CUSIP Number | 162828107 |
| ISIN Number | US1628282063 |
| Employer ID | 47-2568632 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James F. Oliviero III, C.F.A. | President, Chief Executive Officer and Director |
| William Garrett Gray | Chief Financial Officer, Corporate Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | EFFECT | Notice of Effectiveness |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 22, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |